Currently Viewing:
Newsroom
Currently Reading
Researchers Report on Use of Nanopore Technology to Detect AML Biomarkers
December 22, 2019 – Sara Karlovitch
The Value of Genomic Profiling for Women With Breast Cancer
December 15, 2019 – Laura Joszt
At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow
December 14, 2019 – AJMC Staff
5 Things About Cancer, Genetics, and Germline Screening
December 06, 2019 – Allison Inserro
NCCN Releases Updated Breast, Pancreatic, Ovarian Genetic Screening Guidelines
December 05, 2019 – Allison Inserro
Researchers Use Tumor Slices to Understand Microenvironment, Test Therapeutics
November 28, 2019 – AJMC Staff
Pancreatic Tumor Classification Could Guide Treatment, Researchers Say
November 22, 2019 – AJMC Staff
RNA Sequencing May Be Able to Help Target Therapies for Pediatric Cancers
November 16, 2019 – Laura Joszt
Researchers Identify mRNA Biomarker to Predict Response to Chemotherapy
November 09, 2019 – AJMC Staff

Researchers Report on Use of Nanopore Technology to Detect AML Biomarkers

Sara Karlovitch
Nanopore technology, still in its developmental phases, could be used to detect predictive biomarkers for acute myeloid leukemia (AML), according to a recent study.
Nanopore technology has shown to be effective in helping to quickly detect acute myeloid leukemia (AML) predictive biomarkers for prognostic stratification, according to a new study published in Genes.

Currently, next-generation sequencing (NGS) is used for gene detection, however, according to study authors, that method is time consuming (up to 7 days) and costly. Timing is of the essence in AML predictive biomarker detection and researchers state that nanopore technology is a scalable, faster, and more cost-effective technology.

The study included 22 patients with AML. At diagnosis, molecular evaluations were performed for all patients. Researches selected 5 patients who had a complex karyotype to increase the chances of finding cases with the TP53 gene mutation. Nanopore-based assay was used for rapid (24 h) sequencing of 6 genes (NPM1, FLT3CEBPA, TP53, IDH1 and IDH2).

“Through the NGS workflow optimization and innovative custom bioinformatics pipeline, the platform allows the analysis of selected genes useful for diagnosis and treatment decisions in hematologic malignancies within 48 [hours] of specimen collection," researchers wrote. “We propose a workflow that can potentially enable laboratories equipped with only basic molecular biology techniques to perform detailed targeted gene sequencing analysis in AML patients, shortening TAT and reducing costs (minimal IT infrastructure for sequencing and data analysis.”

Researchers say there are pros and cons to both NGS and nanopore technology. Although nanopore-based technology is still in its developmental phases, there have been great improvements in performance. NGS, while extremely powerful, generates short read, which may lead to misassembles and gaps. Large structural variations are also harder to detect using short reads. 

Researchers say that the scalability of the technology is one of the strengths of nanopore testing, as well as being highly cost-effective. Processing the sample costs around $200.

Reference

Cumbo C, Francesco Minervini C, Orsini P, et al. Nanopore targeted sequencing for rapid gene mutations detection in acute myeloid leukemia [published online December 9, 2019]. Genes. doi:10.3390/genes10121026.

Related Articles

Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML
Three Biomarkers Can Predict Long-Term Disease Control in Elderly Patients With MM
As Relevance of MRD Testing Grows, So Does Access
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up